VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (8538)	1/10/2001 9:37:40 PM
From: JMarcus	Read Replies (1) of 9719

Tuck, doesn’t the following press release indicate that CRA isn’t sticking with the build-it-and-they’ll-come model, but is moving full-bore into drug development? biz.yahoo.com In announcing the hiring of Stephen L. Hoffman, M.D., as Sr. V.P., Immunotherapeutics, CRA states that he will “establish and lead a team to create and implement scientific and technical programs designed to develop Celera's potential new discoveries in its proteomics and functional genomics initiatives. Celera intends to uncover important disease targets from its genomics and proteomics data, and to develop vaccines, therapeutic antibodies, and other biologically active molecules for treating and preventing these diseases. Dr. Hoffman and his team will initially focus on specific cancers.” Sounds to me like an entirely new business model for CRA: i.e., drug development. That's a business model the market can readily comprehend. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next